13F Holdings
中文EN

CBIO CRESCENT BIOPHARMA, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1253689 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-58.7%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,216.6%
Net margin-727.6%
FCF margin-549.5%
EBITDA margin-1,214.9%

Returns

ROE-55.8%
ROA-49.9%
ROIC (approx.)—
Asset turnover0.07x

Leverage & solvency

Liabilities / assets8.4%
Debt / equity0.00x
Current ratio12.57x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-12.4%
Payout ratio—
Capex / revenue2.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$10.84M—$10,000$75,000$1.16M
R&D expense$138.09M$14.26M$20.07M$28.39M$47.49M
SG&A expense$25.39M$18.25M$19.21M$19.09M$17.12M
Operating income-$152.63M-$40.04M-$39.28M-$47.40M-$63.45M
Interest expense$2.19M————
Pretax income-$151.94M————
Income tax$2.00M————
Net income-$153.94M-$37.88M-$36.90M-$46.69M-$63.43M
EBITDA-$152.55M-$40.00M-$39.12M-$47.20M-$63.18M
EPS (basic)—-0.59-0.58-0.89-1.23
EPS (diluted)—-0.59-0.58-0.89-1.23
Weighted avg. shares (diluted)—64.48M63.34M52.53M51.45M
Balance sheet
Cash & equivalents$213.19M$34.77M$41.79M$47.87M$90.25M
Receivables$18.00M$0———
Current assets$236.66M$34.80M$43.79M$50.71M$90.79M
PP&E, net$846,000$0—$242,390$368,842
Total assets$240.29M$35.62M$45.32M$51.81M$94.35M
Current liabilities$36.07M$9.61M$6.84M$8.88M$11.82M
Total liabilities$37.28M$47.10M$6.90M$8.88M$12.74M
Shareholders' equity$203.01M-$15.48M$38.41M$42.93M$81.60M
Shares outstanding27.56M1.02M64.39M54.38M52.31M
Cash flow statement
Operating cash flow-$71.53M-$31.10M-$34.88M-$46.46M-$57.49M
Capital expenditure$919,000$9,972$21,394$84,191$14,943
Free cash flow-$72.45M-$31.11M-$34.90M-$46.54M-$57.50M
Investing cash flow-$72.92M$20,028-$21,394-$84,191-$14,943
Financing cash flow$322.98M$5,398$28.82M$4.16M$10.72M
Depreciation & amortization$84,000$35,174$153,301$207,145$264,600
Stock-based compensation$13.30M$4.70M$3.52M$3.86M$6.09M

Free plan shows the latest 5 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.